$STRM
STREAMLINE HEALTH SOLUTIONS INC. Stock $strm

$strm Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924020087 Filed on June 12, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q2
Revenue	$4.330M	$5.361M	$5.332M
YoY Change	-18.79%	-20.52%	-10.16%
Cost Of Revenue	$2.277M	$2.442M	$2.786M
YoY Change	-18.27%	-70.94%	-13.18%
Gross Profit	$2.053M	$2.919M	$2.546M
YoY Change	-19.36%	-275.95%	-6.6%
Gross Profit Margin	47.41%	54.45%	47.75%
Selling, General & Admin	$3.192M	$2.631M	$3.806M
YoY Change	-16.13%	-27.84%	-15.44%
% of Gross Profit	155.48%	90.13%	149.49%
Research & Development	$1.111M	$1.394M	$1.701M
YoY Change	-34.69%	-7.99%	129747.33%
% of Gross Profit	54.12%	47.76%	66.81%
Depreciation & Amortization	$1.120M	$1.067M	$1.059M
YoY Change	5.76%	-75.03%	9.06%
% of Gross Profit	54.55%	36.55%	41.59%
Operating Expenses	$4.303M	$4.025M	$5.507M
YoY Change	-21.86%	2281.66%	-5.26%
Operating Profit	-$2.250M	-$1.106M	-$2.996M
YoY Change	-24.9%	-39.5%	-2.95%
Interest Expense	$465.0K	-$290.0K	$248.0K
YoY Change	87.5%	26.09%	-287.88%
% of Operating Profit
Other Income/Expense, Net	$0.00	$39.00K	$32.00K
YoY Change	-100.0%	-22.0%	-94.0%
Pretax Income	-$2.739M	-$1.357M	-$2.848M
YoY Change	-3.83%	-36.38%	2.59%
Income Tax	$0.00	$13.00K	$53.00K
% Of Pretax Income
Net Earnings	-$2.739M	-$1.370M	-$2.901M
YoY Change	-5.58%	-37.21%	4.09%
Net Earnings / Revenue	-63.26%	-25.55%	-54.41%
Basic Earnings Per Share	-$0.05		-$0.05
Diluted Earnings Per Share	-$0.05	-$0.02	-$0.05
COMMON SHARES
Basic Shares Outstanding	65.36M shares		58.61M shares
Diluted Shares Outstanding			55.97M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.979M	$3.190M	$5.987M
YoY Change	-33.54%	-51.65%	-24.74%
Cash & Equivalents	$3.979M	$3.190M	$5.987M
Short-Term Investments
Other Short-Term Assets	$722.0K	$629.0K	$717.0K
YoY Change	0.7%	-11.41%	69.5%
Inventory
Prepaid Expenses
Receivables	$4.706M	$4.237M	$4.280M
Other Receivables	$294.0K	$780.0K	$535.0K
Total Short-Term Assets	$9.701M	$8.836M	$11.52M
YoY Change	-15.78%	-44.73%	-15.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$76.00K	$88.00K	$99.00K
YoY Change	-23.23%	-20.72%	-64.89%
Goodwill	$13.28M	$13.28M	$23.09M
YoY Change	-42.5%	-42.5%
Intangibles	$11.66M	$12.07M	$14.34M
YoY Change	-18.69%	-18.4%
Long-Term Investments
YoY Change
Other Assets	$1.386M	$1.666M	$1.598M
YoY Change	-13.27%	-1.71%	59.48%
Total Long-Term Assets	$32.02M	$32.90M	$44.97M
YoY Change	-28.78%	-27.75%	-2.78%
TOTAL ASSETS
Total Short-Term Assets	$9.701M	$8.836M	$11.52M
Total Long-Term Assets	$32.02M	$32.90M	$44.97M
Total Assets	$41.73M	$41.74M	$56.49M
YoY Change	-26.13%	-32.16%	-5.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.120M	$1.253M	$299.0K
YoY Change	274.58%	100.16%	-70.48%
Accrued Expenses	$1.777M	$2.023M	$2.505M
YoY Change	-29.06%	-38.04%	-11.89%
Deferred Revenue	$7.351M	$7.112M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.750M	$1.500M	$875.0K
YoY Change	100.0%	100.0%	133.33%
Total Short-Term Liabilities	$12.82M	$13.68M	$14.44M
YoY Change	-11.22%	-18.44%	-3.81%
LONG-TERM LIABILITIES
Long-Term Debt	$10.68M	$7.566M	$8.742M
YoY Change	22.12%	-15.6%	-8.45%
Other Long-Term Liabilities	$931.0K		$143.0K
YoY Change	551.05%		-96.39%
Total Long-Term Liabilities	$11.61M	$9.239M	$8.989M
YoY Change	29.12%	0.04%	-33.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.82M	$13.68M	$14.44M
Total Long-Term Liabilities	$11.61M	$9.239M	$8.989M
Total Liabilities	$24.42M	$22.92M	$23.42M
YoY Change	4.26%	-11.88%	-17.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$118.4M	-$115.7M	-$99.90M
YoY Change	18.55%	19.23%
Common Stock	$617.0K	$134.5M	$133.0M
YoY Change	-99.54%	1.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.30M	$18.81M	$33.06M
YoY Change
Total Liabilities & Shareholders Equity	$41.73M	$41.74M	$56.49M
YoY Change	-26.13%	-32.16%	-5.8%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.739M	-$1.370M	-$2.901M
YoY Change	-5.58%	-37.21%	4.09%
Depreciation, Depletion And Amortization	$1.120M	$1.067M	$1.059M
YoY Change	5.76%	-75.03%	9.06%
Cash From Operating Activities	-$1.199M	-$54.00K	$126.0K
YoY Change	-1051.59%	-97.77%	-109.92%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$12.00K	$29.00K
YoY Change	-100.0%	-97.55%	-105.59%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$232.0K	-$12.00K	-$433.0K
YoY Change	-46.42%	-97.55%	-16.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$250.0K		$125.0K
YoY Change	100.0%
Cash From Financing Activities	$2.220M	699.0K	-$304.0K
YoY Change	-830.26%	-131.93%	115.6%
NET CHANGE
Cash From Operating Activities	-$1.199M	-54.00K	$126.0K
Cash From Investing Activities	-$232.0K	-12.00K	-$433.0K
Cash From Financing Activities	$2.220M	699.0K	-$304.0K
Net Change In Cash	$789.0K	633.0K	-$611.0K
YoY Change	-229.13%	-112.41%	-68.34%
FREE CASH FLOW
Cash From Operating Activities	-$1.199M	-$54.00K	$126.0K
Capital Expenditures	$0.00	$12.00K	$29.00K
Free Cash Flow	-$1.199M	-$66.00K	$97.00K
YoY Change	-1336.08%	-97.73%	-112.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	dei	Amendment Flag AmendmentFlag	false
CY2024Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--01-31
CY2024Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	117000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	86000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	304000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	291000	usd
CY2024Q2	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	8396000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	7960000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4428000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4019000	usd
CY2024Q2	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2024Q2	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
CY2024Q2	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
CY2024Q2	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
CY2024Q2	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
CY2022Q4	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
CY2022Q4	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
CY2022Q4	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
CY2022Q4	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	dei	Document Type DocumentType	10-Q
CY2024Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q2	dei	Document Period End Date DocumentPeriodEndDate	2024-04-30
CY2024Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q2	dei	Entity File Number EntityFileNumber	000-28132
CY2024Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-1455414
CY2024Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	2400 Old Milton Pkwy., Box 1353
CY2024Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Alpharetta
CY2024Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2024Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30009
CY2024Q2	dei	City Area Code CityAreaCode	888
CY2024Q2	dei	Local Phone Number LocalPhoneNumber	997-8732
CY2024Q2	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2024Q2	dei	Trading Symbol TradingSymbol	STRM
CY2024Q2	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q2	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62030026
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3979000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3190000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4706000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4237000	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	294000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	780000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	722000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	629000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	9701000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	8836000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	76000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88000	usd
CY2024Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	5624000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	5798000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11662000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12071000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	13276000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	13276000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1386000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1666000	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	32024000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	32899000	usd
CY2024Q2	us-gaap	Assets Assets	41725000	usd
CY2024Q1	us-gaap	Assets Assets	41735000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1120000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1253000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1777000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2023000	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	1750000	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	1500000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7351000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7112000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	817000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1794000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12815000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13682000	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	7089000	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	7566000	usd
CY2024Q2	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	0	usd
CY2024Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	1500000	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	3587000	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	746000	usd
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2024Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	185000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	173000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11607000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9239000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	24422000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	22921000	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	617000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	590000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	135124000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	133923000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118438000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115699000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	17303000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	18814000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41725000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41735000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4330000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5332000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3192000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3841000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1111000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1701000	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	6580000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	8328000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2250000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2996000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	465000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	248000	usd
CY2024Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-24000	usd
CY2023Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	364000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	32000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2739000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2848000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2739000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2901000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58224090
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55970880
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	18814000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	-0	usd
CY2024Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	67000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	529000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	770000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2739000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	17303000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	35511000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2023Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	179000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	595000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2901000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	33062000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2739000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2901000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1120000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1059000	usd
CY2024Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	152000	usd
CY2023Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2024Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-24000	usd
CY2023Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	364000	usd
CY2024Q2	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	usd
CY2023Q2	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	39000	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	499000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	572000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-17000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-3900000	usd
CY2024Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	100000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	15000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-161000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-327000	usd
CY2024Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-262000	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-795000	usd
CY2024Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	251000	usd
CY2023Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1042000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1199000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	126000	usd
CY2024Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
CY2024Q2	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	232000	usd
CY2023Q2	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	404000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-232000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-433000	usd
CY2024Q2	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	250000	usd
CY2023Q2	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	125000	usd
CY2024Q2	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1500000	usd
CY2023Q2	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	-0	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000	usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	4400000	usd
CY2023Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2024Q2	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	447000	usd
CY2023Q2	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	-0	usd
CY2024Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	16000	usd
CY2023Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	-0	usd
CY2024Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	67000	usd
CY2023Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	179000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2220000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-304000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	789000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-611000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3190000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6598000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3979000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5987000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	29143000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.45	pure
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2024Q2	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	65000	usd
CY2024Q2	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates.</p>
CY2024Q2	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Reclassification</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Certain amounts for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> April 30, 2023</em>, were reclassified to conform to the current period classification. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> April 30, 2023, </em>the Company incurred acquisition-related costs totaling $35,000, consisting primarily of professional service fees. The aforementioned acquisition-related costs for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> April 30, 2023</em>, were previously presented in a separate, single caption and are now included in selling, general, and administrative expense in the accompanying condensed consolidated statements of operations, which is consistent with the presentation for the current period. </p>
CY2023Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	35000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1794000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	159000	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-135000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1794000	usd
CY2024Q2	strm	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Shares FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsShares	690000	usd
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	447000	usd
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	159000	usd
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	-817000	usd
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2024Q2	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-159000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4330000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5332000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2831000	usd
CY2024Q1	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	77000	usd
CY2024Q2	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	123000	usd
CY2024Q1	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	102000	usd
CY2024Q2	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	20000	usd
CY2023Q2	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	18000	usd
CY2024Q2	strm	Deferred Commission Costs Paid And Payable DeferredCommissionCostsPaidAndPayable	1321000	usd
CY2024Q1	strm	Deferred Commission Costs Paid And Payable DeferredCommissionCostsPaidAndPayable	1461000	usd
CY2024Q2	us-gaap	Amortization Of Deferred Sales Commissions AmortizationOfDeferredSalesCommissions	140000	usd
CY2023Q2	us-gaap	Amortization Of Deferred Sales Commissions AmortizationOfDeferredSalesCommissions	129000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	86000	usd
CY2024Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	31000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	117000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	132000	usd
CY2023Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	96000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	499000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	572000	usd
CY2023Q2	us-gaap	Stock Issued1 StockIssued1	23000	usd
CY2024Q2	strm	Professional Fees Noncash ProfessionalFeesNoncash	4000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2739000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2901000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58224090
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55970880
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2687471
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2655831
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	26	pure
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.24	pure
CY2023Q4	us-gaap	Restructuring Costs RestructuringCosts	759000	usd
CY2023Q2	us-gaap	Restructuring Costs RestructuringCosts	0	usd
CY2024Q1	us-gaap	Restructuring Reserve RestructuringReserve	74000	usd
CY2024Q2	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2024Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	65000	usd
CY2024Q2	us-gaap	Restructuring Reserve RestructuringReserve	9000	usd
CY2024Q2	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	759000	usd
CY2024Q2	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	759000	usd
CY2024Q2	us-gaap	Stock Issued1 StockIssued1	30000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	8839000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	9066000	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	3587000	usd
CY2024Q1	us-gaap	Notes Payable NotesPayable	0	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	3587000	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2024Q1	strm	Minimum Adjusted Ebitda MinimumAdjustedEbitda	-5750000	usd
CY2024Q2	strm	Minimum Adjusted Ebitda MinimumAdjustedEbitda	-4560000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000	usd
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.24	pure
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	346000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	340000	usd

Files In Submission

Name	View Source	Status
0001437749-24-020087-index-headers.html	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
0001437749-24-020087-index.html	Edgar Link	pending
0001437749-24-020087.txt	Edgar Link	pending
0001437749-24-020087-xbrl.zip	Edgar Link	pending
ex_622822.htm	Edgar Link	pending
ex_622823.htm	Edgar Link	pending
ex_622824.htm	Edgar Link	pending
ex_622825.htm	Edgar Link	pending
ex_686148.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
strm-20240430.xsd	Edgar Link	pending
strm20240430_10q.htm	Edgar Link	pending
strm-20240430_cal.xml	Edgar Link	unprocessable
strm-20240430_def.xml	Edgar Link	unprocessable
strm-20240430_lab.xml	Edgar Link	unprocessable
strm-20240430_pre.xml	Edgar Link	unprocessable
strm20240430_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STRM
STREAMLINE HEALTH SOLUTIONS INC. Stock $strm

2024 Q2 Form 10-Q Financial Statement

#000143774924020087 Filed on June 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRM STREAMLINE HEALTH SOLUTIONS INC. Stock $strm

2024 Q2 Form 10-Q Financial Statement

#000143774924020087 Filed on June 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRM
STREAMLINE HEALTH SOLUTIONS INC. Stock $strm